ETH-155008

ETH-155008 is an orally bioavailable, small molecule dual kinase inhibitor targeting cyclin-dependent kinases 4 and 6 (CDK4/6) and serine/threonine-protein kinase pim-3 (PIM3), with additional inhibitory activity against Fms-like tyrosine kinase 3 (FLT3)[2][3][4][7]. It was developed by Shengke Pharmaceuticals. The drug is designed to synergistically arrest tumor cells in the G1 phase of the cell cycle and induce apoptosis by simultaneously inhibiting both Pim1/3 and CDK4/6 pathways[7]. This dual inhibition aims to reduce drug resistance associated with CDK4/6 inhibitors while minimizing toxicity compared to combination therapies. Preclinical studies have shown potent antiproliferative effects against human acute myeloid leukemia cells[1]. Clinical development has focused on hematologic malignancies such as acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL), particularly in patients who are refractory or ineligible for standard treatments[5].